# Meropenem vs Cefotaxime as Empirical Treatment of SBP

> **NCT05427747** · PHASE4 · UNKNOWN · sponsor: **Assiut University** · enrollment: 286 (estimated)

## Conditions studied

- Spontaneous Bacterial Peritonitis

## Interventions

- **DRUG:** cefotaxime

## Key facts

- **NCT ID:** NCT05427747
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-01
- **Primary completion:** 2024-01
- **Final completion:** 2024-02
- **Target enrollment:** 286 (ESTIMATED)
- **Last updated:** 2022-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05427747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05427747, "Meropenem vs Cefotaxime as Empirical Treatment of SBP". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05427747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*